Attorney Docket No.: T1590YP Application No.: 10/535,091 Filing Date: May 13, 2005

Page No.: 4

Amendment to the Claims

23. (amended) A method for the treatment of anxiety and/or depression and/or circadian rhythm disorders which comprises administration of an effective amount of a compound selected from: (a) a VR2 polypeptide; (b) a compound which modulates the activity of a VR2 polypeptide; (c) a polynucleotide encoding a VR2 polypeptide; or (d) an antisense polynucleotide to a polynucleotide encoding a VR2 polypeptide, to a patient in need of such treatment.

Claims 24-28. (canceled)

- 29. (previously presented) A method of Claim 23 for achieving a circadian rhythm phase-shifting effect in a mammal.
- 30. (previously presented) A method of Claim 23 for resetting the internal circadian clock in a mammal.
- 31. (previously presented) A method of Claim 23 for shortening the time of reintrainment of circadian rhythms in a mammal.
- 32. (previously presented) A method of Claim 23 for enhancing or improving sleep quality and/or preventing and/or treating sleep disorders and sleep disturbances in a mammal.
- 33. (previously presented) A method of Claim 23 for increasing sleep efficiency and augmenting sleep maintenance in a mammal.
- 34. (previously presented) A method of Claim 23 for the prevention or treatment of a circadian rhythm disorder in a mammal, which disorder is selected from the group consisting of: time- zone change (jet-lag) syndrome, shift-work sleep disorder, delayed sleep-phase syndrome, advanced i sleep-phase syndrome, and non-24-hour sleep- wake disorder.

Attorney Docket No.: T1590YP Application No.: 10/535,091 Filing Date: May 13, 2005

Page No.: 5

35. (previously presented) A method of Claim 23 for the prevention or treatment of a circadian rhythm disorder in a mammal, which disorder is selected from the group consisting of Disorders of Initiating and Maintaining Sleep (insomnias) ("DIMS"), childhood onset DIMS, nocturnal myoclonus and restless legs and non specific REM disturbances as seen in ageing.

Claims 36-42. (canceled)

43. (previously presented) A method of Claim 23 wherein the compound which modulates the activity of a VR2 polypeptide is an antagonist.

Claims 44-54. (canceled)